Table 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
Summary of key outcome parameters of study 2 (BP42595; RG6292 plus atezolizumab 1,200 mg every 3 weeks)
创建时间：
2025-03-10
